Pharmaceuticals

HWPC

HWPC released FY2026 Q1 earnings on April 20 After-Market (BJT), actual revenue CNY 324.55 M, actual EPS CNY 0.2

HWPC FY2026 Q1 Earnings Release on April 21, 2026 After-Market (BJT)

HWPC to Release FY2025 Earnings on April 21 Pre-Market (BJT), Forecast Revenue CNY 1.561 B, EPS CNY 1.3785

HWPC released FY2025 Q4 earnings on February 13 Pre-Market (BJT), actual revenue CNY 418.41 M, actual EPS CNY 0.2145

HWPC released FY2025 Annual Earnings on February 13 Pre-Market (BJT), Actual Revenue CNY 1.504 B (Forecast CNY 1.561 B), Actual EPS CNY 1.77 (Forecast CNY 1.3785)

HWPC released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue CNY 372.11 M, actual EPS CNY 1.0471

HWPC released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 1.086 B, actual EPS CNY 1.5832

HWPC FY2025 Q3 Earnings Release on October 31 After-Market (BJT)

HWPC released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 713.71 M, actual EPS CNY 0.54

HWPC released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 377.48 M, actual EPS CNY 0.226

HWPC to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Warner Pharmaceutical's Shareholder Plans to Reduce Shareholding

Waner Pharmaceutical Shows Significant Potential in Bismuth Chain and ZG-001

Huana Pharmaceutical Obtains BB ESG Rating

Warner Pharma Subsidiary Obtains Approval for Levosalbutamol Raw Material Drug

Huana Pharmaceutical's Potassium and Phosphate Compound Injection Passes Consistency Evaluation

Huana Pharmaceutical's Potassium Phosphate Compound Injection Passes Consistency Evaluation

Huana Pharmaceutical Subsidiary Obtains Magnesium Sulfate API Approval

Huana Pharmaceutical Announces Progress in Innovative Drug R&D

Huana Pharmaceutical Subsidiary Obtains Approval for Acetylcysteine API

159892

516820

159849

688799

Innovative drug concept repeatedly active, ALK straight to the daily limit, Rundu Pharma previously sealed the board, InventisBio, Junshi Biosciences, HWPC, and Biokin Pharmaceutical rose more than 6%

Wallstreetcn

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Rundu Pharma

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

InventisBio

BIOKIN PHARMACEUTICAL

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Junshi Biosciences

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

HWPC announced that its Benidipine Hydrochloride Tablets are expected to win the bid for national centralized drug procurement, with a price of 7.19 yuan per box, and the procurement period lasting until December 31, 2028. The estimated sales revenue for 2024 is 166,300 yuan, and for the first half of 2025, it is 5.0976 million yuan. Winning the bid will help expand sales scale, enhance market share and brand influence, and have a positive impact on future operating performance

Zhitong

HWPC: The company’s benidipine hydrochloride tablets are expected to win the national centralized drug procurement bid

HWPC announced that its wholly-owned subsidiary Hunan HWPC Chiral Pharmaceuticals Co., Ltd. has received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Isoproterenol Hydrochloride and Levonorgestrel Tartrate. Isoproterenol Hydrochloride is used to treat cardiogenic or infectious shock, while Levonorgestrel Tartrate is used to control blood pressure in acute hypotensive states. This will enrich the company's product line and enhance its core competitiveness

HWPC: The subsidiary's raw materials drug has received the approval notice for the listing application

HWPC announced on October 13th that the company recently received the Drug Registration Certificate for polyethylene glycol sodium potassium powder issued by the National Medical Products Administration. This medication is suitable for the treatment of chronic constipation and fecal impaction

HWPC: Obtained the drug registration certificate for Sodium Potassium Polyethylene Glycol

According to the Zhitong Finance APP, HWPC announced that the company recently received the "Notice of Termination of Drug Registration Application" approved and issued by the National Medical Products Administration, agreeing to the company's withdrawal of the registration application for Arolol Hydrochloride Tablets. Arolol Hydrochloride Tablets are mainly used for the treatment of primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor

HWPC withdraws the registration application for Arolol hydrochloride tablets

HWPC announced that from September 1, 2025, to September 12, 2025, shareholder Xu Xiaoqiang cumulatively reduced his holdings by 1.2961 million shares through centralized bidding, accounting for 0.9870% of the company's total share capital, with a reduction price range of 51.75 to 65.54 yuan/share, totaling 75.8397 million yuan; this reduction plan has been completed, and Xu Xiaoqiang currently holds 674,800 shares, accounting for 0.5139%, while Xu Yan's 18.48 million shares have not been reduced

HWPC: Xu Xiaoqiang reduced his holdings by 0.9870% in September

HWPC announced that in the first half of 2025, operating revenue was 714 million yuan, a year-on-year decrease of 3.37%. Net profit was 71.155 million yuan, a year-on-year decrease of 36.95%

HWPC: Net profit of 71.1155 million yuan in the first half of 2025, a year-on-year decrease of 36.95%

688136

300009

688221

Under the decline of innovative drug concepts, SDKX fell more than 9%, while HWPC, ANKE BIO, Froniter Biotechnologies, and several other stocks fell over 5%

SDKX

ANKE BIO

Froniter Biotechnologies

Under the concept of innovative drugs, SDKX fell by more than 9%

According to the announcement from the Zhitong Finance APP, HWPC announced that its shareholder Mr. Xu Xiaoqiang plans to reduce his holdings in the company by no more than 1.3 million shares based on his own funding needs

HWPC shareholder Xu Xiaoqiang plans to reduce holdings of no more than 1.3 million shares

HWPC(688799.SH)